Timely preterm-birth prediction among pregnant women in Medicaid without preterm-birth history.

Objectives: To develop and prospectively validate a novel model incorporating claims and community-level socioeconomic data to predict preterm birth at scale among pregnant Medicaid women with no history of preterm birth (PTB).

Study Design: A longitudinal Texas Medicaid cohort study, with 2-year retrospective model building (October 2015-October 2017) and a 1-year prospective model validation phase (January 2018-December 2018).

Methods: Inclusion criteria were females aged 11 to 55 years with at least 1 live singleton birth and no history of PTB.

Observed Effectiveness of Palivizumab for 29-36-Week Gestation Infants.

Background: Respiratory syncytial virus (RSV) is a common reason for hospitalization of infants. In clinical trials, palivizumab reduced RSV hospitalization rates for premature infants. The 2014 American Academy of Pediatrics clinical practice guideline advised against use of palivizumab for otherwise healthy infants ≥29 weeks' gestation.